NAD+ without prescription: three positions, not one
Almost every page written about NAD+ without prescription collapses three separate legal positions into a single answer, and then gets that answer wrong in one of two directions. Either it claims NAD+ is banned from compounding, which is false, or it implies a compounded product is approved, which is also false. Both errors are common enough that you should expect to meet them.
The three positions are these. A research-use sale, where a vendor sells NAD+ as material labelled for laboratory use and no prescriber exists anywhere in the transaction. A compounded prescription, where a licensed prescriber writes for a preparation that a pharmacy or an outsourcing facility makes from bulk NAD. And clinic administration, where a practice infuses a compounded preparation on site under state medical and nursing law.
Only the first involves no prescription at all. The second and third both do, and the second is the one that surprises people, because on the compounds this site usually covers it does not exist. NAD+ is different, and this page is about being precise rather than reassuring.
The vial at the top of this page is the first route: 1,000 mg at $104.00 list, $52.00 with the code, sold as research material. We earn a commission on it and our affiliate disclosure says so plainly. That is also why we are going to spend the next three sections explaining the route we do not earn anything from.
What FDA 503A category 1 actually says about NAD
FDA maintains a list of bulk drug substances nominated for use in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act, sorted into three categories. The list was last updated on May 14, 2026, and it is a public PDF you can read yourself in about five minutes.
Nicotinamide Adenine Dinucleotide (NAD) appears in category 1, which the document titles Bulk Drug Substances Under Evaluation. So does Nicotinamide Adenine Dinucleotide Disodium Reduced (NADH). That is the entire basis of the compounded prescription route.
Here is what category 1 means, in FDA's own words on its 503A bulks page: FDA does not intend to take action against a compounder for compounding drugs using bulk drug substances listed in category 1, provided that the conditions described in the guidance document are met.
Read that sentence for what it is. It is an interim enforcement policy, adopted so that patient treatment is not disrupted while FDA evaluates nominations. It is a statement about what the agency intends to do, not a finding that the substance is safe or effective, and the category is named under evaluation for a reason. FDA also says explicitly that substances in category 1 stay within that policy only until the agency decides on inclusion in the 503A bulks list, or until it removes them on the basis of, for example, safety information.
So the accurate sentence for a compounded NAD+ preparation is: made from a bulk substance FDA is still evaluating, under a policy of non-enforcement rather than approval, by a compounder who is required to hold a valid certificate of analysis for that substance and to have obtained it from an establishment registered with FDA. Nobody has approved anything.
| Category | What FDA calls it | What it means for a compounder | NAD entries |
|---|---|---|---|
| Category 1 | Bulk Drug Substances Under Evaluation | FDA does not intend to act against a compounder meeting the guidance conditions | Nicotinamide Adenine Dinucleotide (NAD); Nicotinamide Adenine Dinucleotide Disodium Reduced (NADH) |
| Category 2 | Bulk Drug Substances that Raise Significant Safety Risks | FDA would consider action under its general enforcement policies | None. No NAD entry appears here |
| Category 3 | Bulk Drug Substances Nominated Without Adequate Support | Not eligible for the category 1 policy. FDA would consider action | Beta-Nicotinamide Adenine Dinucleotide Disodium Salt Trihydrate |
FDA's 503A bulk drug substances list, updated May 14, 2026. Every NAD entry and where it sits.
Category 2 is where NAD is not, and why that error spreads
If you have read that NAD+ or NADH is category 2, or banned from compounding, that is simply wrong, and it is worth showing you how to check rather than asking you to take our word for it.
Category 2 in the May 2026 list is titled Bulk Drug Substances that Raise Significant Safety Risks, and it is short. It contains six entries: cesium chloride, domperidone, germanium sesquioxide, ibutamoren mesylate, kisspeptin-10, and quinacrine hydrochloride for intrauterine administration. No form of nicotinamide adenine dinucleotide appears in it.
The distinction is not cosmetic. For category 2, FDA says it does not intend to adopt the policy described for category 1 and would consider taking action against a compounder under its general enforcement policies. That is close to the opposite of the position NAD occupies.
Why the error spreads is easy to guess. The categories sound similar, the list is a PDF rather than a web page, and a confident sentence copied between sites never has to be checked. The correction takes one download and one search.
The Beta-NAD trap: the same words, a different category
There is one genuine trap in the same document. Category 3 is titled Bulk Drug Substances Nominated Without Adequate Support, and it contains an entry reading Beta-Nicotinamide Adenine Dinucleotide Disodium Salt Trihydrate. To a reader skimming for the word nicotinamide, that looks like the same substance under a longer name. It sits in a different category with a materially different consequence.
FDA's position on category 3 is that those substances were nominated with insufficient supporting information for the agency to evaluate them, that they are not eligible for the policy that applies to category 1, and that FDA would consider taking action against a compounder using them under its general enforcement policies. Substances can be re-nominated with adequate support, so category 3 is a documentation status rather than a safety judgment, but the enforcement position is what matters to a compounder.
The practical consequence is narrow and worth knowing anyway. If a clinic or a compounder describes the bulk substance it is using by a chemical name rather than plainly as NAD, read the name carefully, because the category it falls into is not decided by how similar the words look. And if anyone quotes the categories at you as evidence of anything, ask which entry they mean and check it against the list.
NAD+ no prescription: what a research-use sale actually is
The NAD+ no prescription route is the one most readers arrive on, and its legal shape is different from everything above. There is no prescriber, no pharmacy, no compounder and no clinic. There is a vendor selling material described as being for laboratory research and not for human consumption, and a buyer.
That description is doing real work in the transaction, and it cuts both ways. It is why the sale can be made without any of the apparatus that surrounds a medicine. It is also why none of the protections that apparatus provides attach to what arrives. No approved label, no manufacturer liability for use in a person, no pharmacist checking anything, no recall route that will find you.
It is worth stating what this page is not saying. Buying research material is not obtaining a medicine by an unofficial route, because it does not become a medicine when it reaches your table. NPR reported in May 2026 that the NAD+ products on the market are not proven to do the average person much good, and nothing in the regulatory position contradicts that.
Two adjacent substances get pulled into this conversation constantly, so a careful word about them. Nicotinamide riboside and nicotinamide mononucleotide are NAD+ precursors sold as supplements in capsule form. They have their own separate regulatory history, which we have not verified for this page and are therefore not going to summarise. Naming them as precursors is accurate. Treating a bottle of capsules as a cheaper version of the vial on this page is not.
| Route | Prescriber required | Who prepares it | Regulatory basis | What you can inspect |
|---|---|---|---|---|
| Research-use vial | No | Nobody. It arrives as powder | Sold as laboratory material, not for human consumption | The certificate of analysis, before you buy |
| Compounded prescription | Yes | A 503A pharmacy or a 503B outsourcing facility | 503A category 1 interim non-enforcement policy | The pharmacy licence, or FDA's registered outsourcing facility list |
| Clinic infusion | Yes, on site | The clinic's compounding chain | Same category 1 policy, plus state medical and nursing law | The clinic licence, and whatever it will put in writing |
Three routes to NAD+, and what each one requires of you.
Is NAD+ legal to buy? The precise answer
Is NAD+ legal to buy is really three questions, and the precise answers differ.
Buying it as research material: this is done openly and at scale across the United States, and the vendors operate as chemical suppliers rather than as pharmacies. What we can say with confidence is what the transaction is and is not. It is not a regulated medical supply, it carries no approval, and nothing about it obliges any regulator to help you if it goes wrong.
Obtaining a compounded NAD+ preparation on prescription: this route exists, and it exists because of the category 1 interim policy described above rather than because anything has been approved. A prescriber writes, a 503A pharmacy or a 503B outsourcing facility prepares, and FDA has said it does not intend to take enforcement action provided the guidance conditions are met.
Receiving an infusion at a clinic: the administration itself is governed by state medical and nursing law, which varies considerably. The product being administered is still a compounded, unapproved preparation. FDA told NPR in 2019 that it has not approved NAD therapy, and nothing in the 2026 list changes that.
The single sentence that survives all three: there is no approved NAD+ product anywhere, so no route on this page ends with an approved medicine. What differs between them is who takes responsibility, how much you pay, and how much of the paperwork you get to see. Our sibling page on how to get NAD+ ranks the routes by friction rather than by law.
The rule that outranks the legal position
In a compounding notice with content current as of 10/30/2024, FDA wrote that it is aware of compounders using food-grade nicotinamide adenine dinucleotide (NAD+) sold by repackagers to make intravenous products. Food-grade ingredients, it said, are not suitable for compounding sterile drugs without appropriate processing, due to the high risk of contamination with microbes and endotoxins. And it recorded adverse event reports after use of NAD+ injectable drugs including severe chills, shaking, vomiting and fatigue, with some requiring medical treatment, reactions consistent with excessive levels of endotoxins.
That is a supply chain problem, not a legal one, and it survives every distinction on this page. A compounded preparation made under a category 1 non-enforcement policy from food-grade bulk is legally better positioned and physically no safer than a research vial from the same repackager. The category tells you about enforcement. The certificate tells you about the batch.
So the question to carry into any of the three routes is the same one: is the material pharmaceutical grade, and does the certificate of analysis for this batch report an endotoxin result, usually labelled LAL or bacterial endotoxins, rather than identity and purity alone. Ask the vendor. Ask the compounder. Ask the clinic. The listing we link states that two independent laboratories test every batch, and we have not been shown an endotoxin figure for the NAD+ batches specifically, so we are not going to imply one exists.
If you want the rest of the buying criteria rather than the legal position, our source assessment sets them out. If you want dosing arithmetic, it lives off this site by design, at PeptideDosage.